Skip to content
Parakho

Sai Parenterals Ltd

NSE SAIPARENTBSE 544742saiparenterals.com

Q1 FY27, unaudited

Revenue
₹178.67 Cr
Profit after tax
₹7.92 Cr

As filed with the exchange, consolidated basis.

Statement of profit and loss

Figures in ₹ crore, reproduced from the results data files the company filed with NSE under Regulation 33 of the SEBI (LODR) Regulations. Nothing is restated, adjusted or estimated.

Statement of profit and loss, consolidated basis
₹ croreQ1 FY27vs a year agoFY26
Revenue from operations178.67—381.00
Other income3.74—8.52
Total income182.41—389.52
Employee benefit expense11.54—29.28
Finance costs9.36—18.44
Depreciation & amortisation8.11—16.85
Total expenses172.62—377.59
Profit before tax9.79—11.93
Tax expense1.87—-2.33
Profit after tax7.92—14.26
Total comprehensive income7.92—14.37
Earnings per share
Earnings per share, basic₹1.79₹4.36
Earnings per share, diluted₹1.79₹4.36

Q1 FY27 — unaudited, from the company’s filing with NSE. Source

FY26 — from the company’s filing with NSE. Source

Why the dash

Parakho has not ingested this company’s year-ago quarter, so the change column stays empty. A dash means we do not hold the figure — never that it is zero.

Earnings call

Q4 FY26

Sai Parenterals reported its first earnings call as a listed company, discussing FY26 results and the acquisition of Australia-based Noumed Pharmaceuticals completed on 12th November 2025. Standalone FY26 revenue grew 30% to about INR162 crore while consolidated revenue rose to INR381 crore including partial-year Noumed contribution. Management outlined a INR440 crore capex program across India and Australia and set out targets for FY27 revenue and EBITDA margin.

Generated by AI from the filed transcript; every statement on the full page carries its verbatim quote. Read the cited summary

Filings

12 shown · 46 published by the exchange

BSE corporate announcements, classified by Parakho. The exchange’s own category is kept alongside our classification so a reclassification never rewrites history.

Page generated from filings held to 25 Aug 2026.